Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Chlorendic acid
Related Products

Hot Products

Basic Information Post buying leads Suppliers
Name

Chlorendic acid

 EINECS 204-078-9
CAS No. 115-28-6 Density 2 g/cm3
PSA 74.60000 LogP 3.23350
Solubility N/A Melting Point 239-242 °C
Formula C9H4Cl6O4 Boiling Point 471.7 °C at 760 mmHg
Molecular Weight 388.846 Flash Point 239.1 °C
Transport Information N/A Appearance solid
Safety 53-22-26-36/37/39-45 Risk Codes 40-41
Molecular Structure Molecular Structure of 115-28-6 (Chlorendic acid) Hazard Symbols IrritantXi
Synonyms

5-Norbornene-2,3-dicarboxylicacid, 1,4,5,6,7,7-hexachloro- (6CI,8CI);1,4,5,6,7,7-Hexachloro-5-norbornene-2,3-dicarboxylicacid;1,4,5,6,7,7-Hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid;2H,3H-Hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylicacid;HET acid;Hexachloroendomethylenetetrahydrophthalicacid;NSC 22231;NSC 41876;

 

Chlorendic acid Synthetic route

cadmium(II) nitrate tetrhydrate

115-28-6

Chlorendic acid

7732-18-5

water

68-12-2, 33513-42-7

N,N-dimethyl-formamide

[Cd8(chlorendic acid(-2H))8(N,N-dimethylformamide)4(H2O)12]·8(N,N-dimethylformamide)

Conditions
ConditionsYield
In water for 504h;56%
115-28-6

Chlorendic acid

107-19-7

propargyl alcohol

114646-85-4

Di-2-propinylchlorendat

Conditions
ConditionsYield
With toluene-4-sulfonic acid Heating;
115-28-6

Chlorendic acid

2157-19-9

1,2,3,4,7,7-hexachloro-5,6-bis(hydroxymethyl)bicyclo<2.2.1>hept-2-ene

Conditions
ConditionsYield
With lithium aluminium tetrahydride In diethyl ether Heating;
115-28-6

Chlorendic acid

56-35-9

bis(tri-n-butyltin)oxide

(C4H9)3SnOOCC7H2Cl6COOH

Conditions
ConditionsYield
In benzene byproducts: H2O; mole ratio of (C4H9)3SnOSn(C4H9)3 and carboxylic acid 1:2; at 20°C or at reflux temp. to remove of water formed by azeotropic distn.;
115-28-6

Chlorendic acid

74-86-2

acetylene

1,4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxylic acid divinyl ester

Conditions
ConditionsYield
decacarbonyldirhenium(0) In xylene at 160℃; under 15001.5 Torr; for 6h; Product distribution / selectivity;
(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

115-28-6

Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions
ConditionsYield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;
(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

115-28-6

Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions
ConditionsYield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;
(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

115-28-6

Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions
ConditionsYield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;
(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

115-28-6

Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions
ConditionsYield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;
(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

115-28-6

Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions
ConditionsYield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

Chlorendic acid Chemical Properties

Product Name: Chlorendic acid (CAS NO.115-28-6)
IUPAC Name: 1,2,3,4,7,7-Hexachlorobicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid 
 
MF: C9H4Cl6O4
MW: 388.84
EINECS: 204-078-9
Mol File: 115-28-6.mol
MP: 239-242 °C(lit.)
Surface Tension: 77.2 dyne/cm 
Density: 2 g/cm3 
Flash Point: 239.1 °C 
Enthalpy of Vaporization: 80.46 kJ/mol 
Boiling Point: 471.7 °C at 760 mmHg 
Vapour Pressure: 3.37E-10 mmHg at 25°C 
Stability: Stable. Incompatible with strong oxidizing agents. 
Product Categories: Organics; Alicyclic/Etch-Resistant Monomers; Lithography Monomers; Self Assembly&Contact Printing

Chlorendic acid Uses

 Product Name: Chlorendic acid (CAS NO.115-28-6) is a variety of intermediate compounds.

Chlorendic acid Production

Product Categories:Organics;Alicyclic/Etch-Resistant Monomers;Lithography Monomers;Self Assembly&Contact Printing

Chlorendic acid Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
rat LC inhalation > 790mg/m3/4H (790mg/m3)   National Technical Information Service. Vol. OTS0537100,
rat LD oral > 1gm/kg (1000mg/kg)   National Technical Information Service. Vol. OTS0535786,

Chlorendic acid Safety Profile

Safety Information of Product Name: Chlorendic acid (CAS NO.115-28-6):
Hazard Codes:  Xi
Risk Statements:  40-41
40:Limited evidence of a carcinogenic effect
41:Risk of serious damage to eyes
Safety Statements:  53-22-26-36/37/39-45
53:Avoid exposure - obtain special instruction before use
22:Do not breathe dust
26: When using 1,2,3,4,7,7-hexachlorobicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid (115-28-6 ),in case of contact with eyes, rinse immediately with plenty of water and seek medical advice
36/37/39:Wear suitable protective clothing, gloves and eye/face protection
45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
WGK Germany:  3
RTECS : RB9000000

Chlorendic acid Specification

  Chlorendic acid , its CAS NO. is 115-28-6, the synonyms are Chlorendic acid ; Labotest-bb lt00159272 ; het acid ; hexachloro-endo-methylenetetrahydrophthalic acid ; 1,4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxylic acid ; 1,4,5,6,7,7-hexachlorobicyclo[2.2.1]-5-heptene-2,3-dicarboxylic acid ; 1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid ; 1,4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxy .

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 115-28-6